1. |
Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the beaver dam eye study[J]. Trans Am Ophthalmol Soc, 2000, 98: 133-141.
|
2. |
Ho M, Liu DT, Lam DS, et al. Retinal vein occlusions, from basics to the latest treatment[J]. Retina, 2016, 36(3): 432-448. DOI: 10.1097/IAE.0000000000000843.
|
3. |
邓玉梦, 黄珍, 叶娅, 等. 强反射点与视网膜分支静脉阻塞和中央静脉阻塞患者血脂水平和炎症指标的相关性[J]. 中华眼底病杂志, 2021, 37(2): 115-121. DOI: 10.3760/cma.j.cn511434-20201102-00526.Deng YM, Huang Z, Ye Y, et al. Association between hyper-reflective dots on spectral-domain optical coherence tomography and lipid levels and systemic inflammatory factors in patients with branch or central retinal vein occlusion[J]. Chin J Ocul Fundus Dis, 2021, 37(2): 115-121. DOI: 10.3760/cma.j.cn511434-20201102-00526.
|
4. |
Campochiaro PA, Wykoff CC, Brown DM, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study[J]. Ophthalmol Retina, 2018, 2(4): 320-328. DOI: 10.1016/j.oret.2017.07.013.
|
5. |
Liang X, Shen B, Ou Z, et al. Comparison of intravitreal ranibizumab monotherapy vs. Ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion[J/OL]. Front Med (Lausanne), 2022, 9: 930508[2022-09-12]. https://pubmed.ncbi.nlm.nih.gov/36172537/. DOI: 10.3389/fmed.2022.930508.
|
6. |
Vinkovic M, Bosnar D, Tedeschi Reiner E, et al. Combined treatment with bevacizumab and triamcinolone acetonide for macular edema due to retinal vein occlusion[J]. Acta Clin Croat, 2020, 59(4): 569-575. DOI: 10.20471/acc.2020.59.04.01.
|
7. |
朱晶, 吴超琼, 肖泽锋. 玻璃体腔注射雷珠单抗联合地塞米松缓释剂治疗视网膜静脉阻塞继发黄斑水肿[J]. 国际眼科杂志, 2024, 24(1): 117-121. DOI: 10.3980/j.issn.1672-5123.2024.1.23.Zhu J, Wu CQ, Xiao ZF. Combination of ranibizumab and dexamethasone. intravitreal implant for macular edema secondary to retinal vein occlusion[J]. Int Eye Sci, 2024, 24(1): 117-121. DOI: 10.3980/j.issn.1672-5123.2024.1.23.
|
8. |
徐玥, 谢驰, 方严. 地塞米松玻璃体腔植入剂起始联合雷珠单抗新策略在视网膜静脉阻塞继发黄斑水肿治疗中的应用[J]. 中华眼底病杂志, 2022, 38(9): 729-738. DOI: 10.3760/cma.j.cn511434-20211102-00626.Xu Y, Xie C, Fang Y. Application of a new strategy of initial combination therapy with intravitreal dexamethasone intravitreal implant and ranibizumab in macular edema secondary to retinal vein occlusion[J]. Chin J Ocul Fundus Dis, 2022, 38(9): 729-738. DOI: 10.3760/cma.j.cn511434-20211102-00626.
|
9. |
Horozoglu F, Sener H, Polat OA, et al. Predictive impact of optical coherence tomography biomarkers in anti-vascular endothelial growth factor resistant macular edema treated with dexamethasone implant[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103167[2022-10-17]. https://pubmed.ncbi.nlm.nih.gov/36261095/. DOI: 10.1016/j.pdpdt.2022.103167.
|
10. |
Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, et al. Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant[J]. BMC Ophthalmol, 2022, 22(1): 191. DOI: 10.1186/s12886-022-02415-w.
|
11. |
Yiu G, Welch RJ, Wang Y, et al. Spectral-domain oct predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion[J]. Ophthalmol Retina, 2020, 4(1): 67-76. DOI: 10.1016/j.oret.2019.08.009.
|
12. |
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the european society of retina specialists (euretina)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
|
13. |
Battaglia Parodi M, Iacono P, Scaramuzzi M, et al. Outer retinal layer changes after dexamethasone implant for central retinal vein occlusion[J]. Retina, 2017, 37(10): 1888-1895. DOI: 10.1097/IAE.0000000000001429.
|
14. |
Haritoglou C, Maier M, Neubauer AS, et al. Current concepts of pharmacotherapy of diabetic macular edema[J]. Expert Opin Pharmacother, 2020, 21(4): 467-475. DOI: 10.1080/14656566.2020.1713093.
|
15. |
Shin HJ, Chung H, Kim HC. Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion[J/OL]. Acta Ophthalmol, 2011, 89(1): e35-e40[2010-12-14]. https://pubmed.ncbi.nlm.nih.gov/21155986/. DOI: 10.1111/j.1755-3768.2010.02063.x.
|
16. |
Babiuch AS, Han M, Conti FF, et al. Association of disorganization of retinal inner layers with visual acuity response to anti-vascular endothelial growth factor therapy for macular edema secondary to retinal vein occlusion[J]. JAMA Ophthalmol, 2019, 137(1): 38-46. DOI: 10.1001/jamaophthalmol.2018.4484.
|
17. |
Moon BG, Cho AR, Kim YN, et al. Predictors of refractory macular edema after branch retinal vein occlusion following intravitreal bevacizumab[J]. Retina, 2018, 38(6): 1166-1174. DOI: 10.1097/IAE.0000000000001674.
|
18. |
Chan EW, Eldeeb M, Sun V, et al. Disorganization of retinal inner layers and ellipsoid zone disruption predict visual outcomes in central retinal vein occlusion[J]. Ophthalmol Retina, 2019, 3(1): 83-92. DOI: 10.1016/j.oret.2018.07.008.
|
19. |
茹月, 师燕芸, 孔帆. 外界膜及椭圆体带完整性与视网膜静脉阻塞黄斑水肿视力预后的相关性[J]. 中华眼视光学与视觉科学杂志, 2023, 25(2): 133-138. DOI: 10.3760/cma.j.cn115909-20220414-00143.Ru Y, Shi YR, Kong F. Association between the integrity of the external limiting membrane and ellipsoid zone and visual outcome in retinal vein occlusion-macular edema[J]. Chin J Optom Ophthalmol Vis Sci, 2023, 25(2): 133-138. DOI: 10.3760/cma.j.cn115909-20220414-00143.
|
20. |
Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, et al. Effect of dexamethasone intravitreal implant on visual acuity and foveal photoreceptor integrity in macular edema secondary to retinal vascular disease[J]. Ophthalmologic, 2021, 244(1): 83-92. DOI: 10.1159/000512195.
|
21. |
Seo KH, Yu SY, Kim M, et al. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns[J]. Retina, 2016, 36(3): 588-595. DOI: 10.1097/IAE.0000000000000770.
|
22. |
De S, Saxena S, Kaur A, et al. Sequential restoration of external limiting membrane and ellipsoid zone after intravitreal anti-VEGF therapy in diabetic macular oedema[J]. Eye (Lond), 2021, 35(5): 1490-1495. DOI: 10.1038/s41433-020-1100-0.
|
23. |
Wirth MA, Wons J, Freiberg FJ, et al. Impact of long-term intravitreal anti-vascular endothelial growth factor on preexisting microstructural alterations in diabetic macular edema[J]. Retina, 2018, 38(9): 1824-1829. DOI: 10.1097/IAE.0000000000001788.
|
24. |
Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial[J]. JAMA Ophthalmol, 2019, 137(11): 1256-1264. DOI: 10.1001/jamaophthalmol.2019.3305.
|
25. |
Kucuk B, Sirakaya E, Karaca C. Comparison of ranibizumab versus aflibercept in treating macular edema among patients with serous retinal detachment secondary to branch retinal vein occlusion[J]. Ocul Immunol Inflamm, 2021, 29(2): 403-410. DOI: 10.1080/09273948.2019.1681474.
|
26. |
陈兰. 视网膜静脉阻塞继发黄斑水肿的抗VEGF治疗方案的研究进展[J]. 眼科学报, 2021, 36(5): 371-379. DOI: 10.3978/j.issn.1000-4432.2021.04.08.Chen L. Research progress in anti-vascular endothelial growth factor treatment regimens for macular edema secondary to retinal vein occlusion[J]. Eye Science, 2021, 36(5): 371-379. DOI: 10.3978/j.issn.1000-4432.2021.04.08.
|
27. |
Chatziralli I, Theodossiadis G, Chatzirallis A, et al. Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data[J]. Retina, 2018, 38(3): 559-568. DOI: 10.1097/IAE.0000000000001579.
|
28. |
de Salles MC, Epstein D. Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion[J]. Graefe's Arch Clin Exp Ophthalmol, 2021, 259(9): 2653-2660. DOI: 10.1007/s00417-021-05146-8.
|
29. |
Shah PN, Shanmugam MP, Vora UB, et al. Long-term real-world outcomes in retinal vein occlusions: how close are we to the trials?[J]. Indian J Ophthalmol, 2022, 70(12): 4370-4375. DOI: 10.4103/ijo.IJO_1330_22.
|
30. |
Spooner KL, Fraser-Bell S, Hong T, et al. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion[J]. Eye (Lond), 2022, 36(6): 1194-1201. DOI: 10.1038/s41433-021-01620-z.
|
31. |
Hoerauf H, Feltgen N, Weiss C, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (comrade c): a european label study[J]. Am J Ophthalmol, 2016, 169: 258-267. DOI: 10.1016/j.ajo.2016.04.020.
|
32. |
Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant[J]. Ocul Immunol Inflamm, 2017, 25(6): 834-840. DOI: 10.1080/09273948.2016.1184284.
|
33. |
Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12): 2453-2460. DOI: 10.1016/j.ophtha.2011.05.014.
|
34. |
Singer MA, Jansen ME, Tyler L, et al. Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series[J]. Clin Ophthalmol, 2017, 11: 31-38. DOI: 10.2147/OPTH.S119373.
|
35. |
Lamprakis I, Todorova MG, Grub M, et al. The impact of multiple intravitreal anti-vegf injections on intraocular pressure[J]. Klin Monbl Augenheilkd, 2018, 235(11): 1278-1284. DOI: 10.1055/s-0043-118851.
|
36. |
Hu Q, Li H, Xu W, et al. Comparison between ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: a systematic review and meta-analysis of randomized controlled trials[J]. Indian J Ophthalmol, 2019, 67(11): 1800-1809. DOI: 10.4103/ijo.IJO_382_19.
|